Target-directed cancer: protein-ligand interactions
Drug Target Review
NOVEMBER 1, 2023
In 2001, he joined Astex Pharmaceuticals in Cambridge where he became an expert in fragment-based drug discovery working on diabetes, thrombotic and oncology drug targets. In 2019 he became Reader in Structural Biology and Cancer Drug Discovery.
96 
Let's personalize your content